Page 6 - Database Consortium News Today

Molecular biomarkers are needed to assess disease prognosis in patients with metastatic clear cell renal cell carcinoma treated with nivolumab.

Molecular biomarkers are needed to assess disease prognosis in patients with metastatic clear cell renal cell carcinoma treated with nivolumab.

Real-world data confirm pazopanib to be safe and effective in patients with metastatic renal cell carcinoma.

/PRNewswire/ -- The COVID-19 Research Database, a pro bono initiative led by numerous leading healthcare organizations, including Change Healthcare, Datavant,...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Iodine concentration and Hounsfield units are independent prognostic biomarkers for metastatic renal cell carcinoma, a study suggests.

Innovative machine learning method for response to immunotherapy

email article Elevated BMI was tied to improved survival in metastatic renal cell carcinoma (RCC) patients treated with immune checkpoint inhibitors, a retrospective study found. In the analysis of more than 700 metastatic RCC patients who received PD-1/L1 immunotherapies, those with a BMI of 25 or greater had significantly longer overall survival (OS), with 1-year rates of 79% versus 66% for those with a BMI below that cutoff (HR 0.75, 95% CI 0.57-0.97, P=0.03), Toni Choueiri, MD, of Da...

SHARE ASCO GU 2021: TIVO-3: Tivozanib in Patients with Advanced Renal Cell Carcinoma Who Have Progressed After Treatment with Axitinib Published 14 February 2021 (UroToday.com) Tivozanib is a potent and highly selective VEGF receptor tyrosine kinase inhibitor in clinical development for renal cell carcinoma (RCC). Axitinib is also a potent and selective VEGF-receptor inhibitor now commonly part of front-line advanced RCC treatment. In the TIVO-3 trial, tivozanib demonstrated significantly gr...

Press release content from Business Wire. The AP news staff was not involved in its creation. Exelixis Announces Positive Findings at ASCO GU for CABOMETYX® (cabozantinib) in Patients with Brain Metastases from Renal Cell Carcinoma February 8, 2021 GMT ALAMEDA, Calif.--(BUSINESS WIRE)--Feb 8, 2021-- Exelixis, Inc. (NASDAQ: EXEL) today announced results from a retrospective analysis evaluating CABOMETYX ® (cabozantinib) activity in brain metastases in patients with renal cell carcinoma (RCC). ...